SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8744)6/23/2003 10:08:52 AM
From: Icebrg  Read Replies (2) | Respond to of 52153
 
>>R&D at BGEN has been something of a disappointment>>

That was more or less the point I was trying to make - perhaps not so well. Biogen has spent between 300 and 370 mUSD on R&D over each of the last three years. With so little to show for it, that the BoD gives up and hands the control of the company over to Idec. (There are of course also problems on the Inteferon side of the business with Rebiff making inroads in the US).

Is this a case of an extremely incompetent R&D management or a realistic appreciation of the problems of developing biotech based drugs? As a biotech investor I would like to know.

Erik



To: Biomaven who wrote (8744)6/24/2003 12:09:46 AM
From: Londo  Read Replies (1) | Respond to of 52153
 
Your side comment of any 6B biotech wanting to take out SEPR while it was at 5 bucks - what makes you think they didn't try? I could easily see, given the current climate out there, that management would want to entrench itself.. especially in the case of SEPR, where you can give yourself half the company in options that vest in two years...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News